Education
About Us
Working with TipRanks
Follow Us
Allurion Technologies (ALUR)
NYSE:ALUR
ALUR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.93 - $20.00
Previous CloseN/A
Volume63.90K
Average Volume (3M)42.36K
Market Cap
$15.91M
Enterprise Value$35.54M
Total Cash (Recent Filing)$12.72M
Total Debt (Recent Filing)$30.52M
Price to Earnings (P/E)―
Beta2.42
Next Earnings
Nov 17, 2025EPS Estimate
-1.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding7,762,681
10 Day Avg. Volume46,551
30 Day Avg. Volume42,362
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.31
Price to Sales (P/S)0.75
P/FCF Ratio-0.56
Enterprise Value/Market Cap2.23
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit2.89
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$6.00Price Target Upside192.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Growth InitiativesOperating expenses of $9.4M were down 48% year over year, as the company continues to closely control spending while prioritizing its growth initiatives.
Regulatory ApprovalThe Audacity findings are considered sufficiently strong to support US approval, with an anticipated approval following a one-year regulatory review.
Weight Loss StudyThe study succeeded in the responder rate co-primary endpoint, with 58% of Allurion balloon patients losing more than 5% of their total body weight at 48 weeks, a statistically significant result.
Bears Say
Clinical Trial ResultsThe mean difference in total body weight loss between the groups was 3.77%, resulting in a 2.69% superiority margin, which was less than the pre-specified 3.0% superiority margin needed to meet the second co-primary endpoint.
Product Realignment ImpactSales were hurt by the intra-quarter decision to realign toward distributors with physician networks that prescribe GLP-1s.
Revenue PerformanceRevenue was $3.4M, which fell short of the $5.2M consensus.
Allurion Technologies News
ALUR FAQ
What was Allurion Technologies’s price range in the past 12 months?
Allurion Technologies lowest stock price was $1.93 and its highest was $20.00 in the past 12 months.
What is Allurion Technologies’s market cap?
Allurion Technologies’s market cap is $15.91M.
When is Allurion Technologies’s upcoming earnings report date?
Allurion Technologies’s upcoming earnings report date is Nov 17, 2025 which is in 39 days.
How were Allurion Technologies’s earnings last quarter?
Allurion Technologies released its earnings results on Aug 13, 2025. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$0.893 by -$0.387.
Is Allurion Technologies overvalued?
According to Wall Street analysts Allurion Technologies’s price is currently Undervalued.
Does Allurion Technologies pay dividends?
Allurion Technologies does not currently pay dividends.
What is Allurion Technologies’s EPS estimate?
Allurion Technologies’s EPS estimate is -1.97.
How many shares outstanding does Allurion Technologies have?
Allurion Technologies has 7,762,681 shares outstanding.
What happened to Allurion Technologies’s price movement after its last earnings report?
Allurion Technologies reported an EPS of -$1.28 in its last earnings report, missing expectations of -$0.893. Following the earnings report the stock price went down -1.55%.
Which hedge fund is a major shareholder of Allurion Technologies?
Currently, no hedge funds are holding shares in ALUR
Allurion Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (192.68% Upside)
$6.00 (192.68% Upside)
Blogger Sentiment
Bullish
ALUR Sentiment 70%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 490.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.36%
12-Months-Change
Fundamentals
Return on Equity
38.80%
Trailing 12-Months
Asset Growth
-39.49%
Trailing 12-Months
Company Description
Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
ALUR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company undergoing a significant strategic pivot with promising long-term potential. While the strategic changes and R&D advancements show promise, the company faces short-term challenges, including a substantial revenue decline and expected disruptions due to restructuring. The sentiment balances between optimism for future growth and the current financial hurdles.View all ALUR earnings summariesALUR Stock 12 Month Forecast
Average Price Target
$6.00
▲(192.68% Upside)
Technical Analysis
Ownership Overview
15.57% Insiders
1.11% Mutual Funds
33.48% Other Institutional Investors
49.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---